Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis

Clinical and Experimental Immunology

Volumn 180, Issue 2, 2015, Pages 243-249

  Rodriguez Martin E ^a,b,c   Picon C ^a,b   Costa Frossard, L ^a,b,c   Alenda, R ^a,b,c   Sainz de la Maza, S ^a   Roldan E ^a,b,c   Espino M ^a,b,c   Villar, L M ^a,b,c   Alvarez Cermeno J C ^a,b,c,d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^c REEM   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

CSF; Innate immunity; Multiple sclerosis; Natural killer cells; Neuroinflammation

Indexed keywords

BETA1A INTERFERON; CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; INTERFERON BETA SERINE; STEROID; NCAM1 PROTEIN, HUMAN;

ADULT; ARTICLE; BRAIN VASCULITIS; CELL EXPANSION; CEREBROSPINAL FLUID; COMPARATIVE STUDY; DISEASE ACTIVITY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HEADACHE; HERPES SIMPLEX ENCEPHALITIS; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NATURAL KILLER CELL; NATURAL KILLER T CELL; NERVOUS SYSTEM INFLAMMATION; PACHYMENINGITIS; PARANEOPLASTIC NEUROPATHY; POSTINFECTIOUS CEREBELITIS; PRIORITY JOURNAL; CLINICAL TRIAL; IMMUNOLOGY; PATHOLOGY;

ANTIGENS, CD56; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER T-CELLS;

EID: 84927623814     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12580     Document Type: Article

References (37)

1. Mayo L, Quintana FJ, Weiner HL. The innate immune system in demyelinating disease. Immunol Rev 2012; 248:170-187.
2. Hao J, Liu R, Piao W etal. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 2010; 207:1907-1921.
3. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-640.
4. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503-510.
5. Catalfamo M, Henkart PA. Perforin and the granule exocytosis cytotoxicity pathway. Curr Opin Immunol 2003; 15:522-527.
6. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136:4480-4486.
7. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25:297-336.
8. Carrega P, Bonaccorsi I, Di Carlo E etal. CD56 (bright) perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J Immunol 2014; 192:3805-3815.
9. Mavilio D, Lombardo G, Benjamin J etal. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005; 102:2886-2891.
10. González VD, Falconer K, Björkström NK etal. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol 2009; 183:6612-6618.
11. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008; 15:226-233.
12. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002; 3:216-227.
13. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 2010; 221:7-14.
14. Antel JP, McCrea E, Ladiwala U, Qin YF, Becher B. Non-MHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression. J Immunol 1998; 160:1606-1611.
15. Lunemann A, Lunemann JD, Roberts S etal. Human NK cells kill resting but not activated microglia via NKG2D and NKp46-mediated recognition. J Immunol 2008; 181:6170-6177.
16. Hammarberg H, Lidman O, Lundberg C etal. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000; 20:5283-5291.
17. Xu W, Fazekas G, Hara H, Tabira T. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 163:24-30.
18. Alvermann S, Henning C, Stüve O, Wiendl H, Stangel M. Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis. In search of biomarkers. JAMA Neurol 2014; 71:905-912.
19. Cepok S, Jacobsen M, Schock S etal. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001; 124:2169-2176.
20. Hamann I, Dörr J, Glumm R etal. Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. J Neuroimmunol 2013; 254:165-169.
21. Kowarik MC, Grummel V, Wremlinger S etal. Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. J Neurol 2014; 261:130-143.
22. Han S, Lin YC, Wu T etal. Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol 2014; 192:2551-2563.
23. Bielekova B, Richert N, Herman ML etal. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 2011; 77:1877-1886.
24. Polman CH, Reingold SC, Banwell B etal. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292-302.
25. Teunissen C, Menge T, Altintas A etal. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler J 2013; 19:1802-1809.
26. Masjuan J, Álvarez-Cermeño JC, García-Barragán N etal. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006; 66:576-578.
27. Benczur M, Petranyl GG, Palffy GY etal. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin Exp Immunol 1980; 39:657-662.
28. Merril J, Jondal M, Seeley J, Ullberg M, Siden A. Decreased NK killing in patients with multiple sclerosis: an analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity of the disease. Clin Exp Immunol 1982; 47:419-430.
29. Kastrukoff LF, Lau A, Wee R, Zecchini D, White R, Paty DW. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J Neuroimmunol 2003; 145:103-114.
30. bright natural killer cells mediate immunomodulatory effects of IL-2R-alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103:5941-5946.
31. Martínez-Rodríguez JE, López-Botet M, Muntels E etal. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin Immunol 2011; 141:348-356.
32. bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007; 28:121-126.
33. Brando B, Barnett D, Janossy G etal. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. Cytometry 2000; 42:327-346.
34. Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity. Front Immunol 2014; 5:543.
35. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011; 11:131-142.
36. Gigli G, Caielli S, Cutuli D, Falcone M. Innate immunity modulates autoimmunity: type 1 interferon-β treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 2007; 122:409-417.
37. Fuss IJ, Joshi B, Yang Z etal. IL-13Rα2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis. Gut 2014; 63:1728-1736.